A
Anouk Allgeier
Researcher at European Organisation for Research and Treatment of Cancer
Publications - 25
Citations - 26465
Anouk Allgeier is an academic researcher from European Organisation for Research and Treatment of Cancer. The author has contributed to research in topics: Temozolomide & Lomustine. The author has an hindex of 20, co-authored 25 publications receiving 22929 citations. Previous affiliations of Anouk Allgeier include University of Lausanne.
Papers
More filters
Journal ArticleDOI
Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Roger Stupp,Warren P. Mason,Martin J. van den Bent,Michael Weller,Barbara Fisher,Martin J.B. Taphoorn,Karl Belanger,Alba A. Brandes,Christine Marosi,Ulrich Bogdahn,Jürgen Curschmann,Robert C. Janzer,Samuel K. Ludwin,Thierry Gorlia,Anouk Allgeier,Denis Lacombe,J. Gregory Cairncross,Elizabeth Eisenhauer,René O. Mirimanoff +18 more
TL;DR: The addition of temozolomide to radiotherapy for newly diagnosed glioblastoma resulted in a clinically meaningful and statistically significant survival benefit with minimal additional toxicity.
Journal ArticleDOI
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial
Roger Stupp,Monika E. Hegi,Warren P. Mason,Martin J. van den Bent,Martin J.B. Taphoorn,Robert C. Janzer,Samuel K. Ludwin,Anouk Allgeier,Barbara Fisher,Karl Belanger,Peter Hau,Alba A. Brandes,J.M.M. Gijtenbeek,Christine Marosi,Charles J. Vecht,Karima Mokhtari,Pieter Wesseling,Salvador Villà,Elizabeth Eisenhauer,Thierry Gorlia,Michael Weller,Denis Lacombe,J. Gregory Cairncross,René-Olivier Mirimanoff +23 more
TL;DR: Benefits of adjuvant temozolomide with radiotherapy lasted throughout 5 years of follow-up, and a benefit of combined therapy was recorded in all clinical prognostic subgroups, including patients aged 60-70 years.
Journal ArticleDOI
Adjuvant Procarbazine, Lomustine, and Vincristine Chemotherapy in Newly Diagnosed Anaplastic Oligodendroglioma: Long-Term Follow-Up of EORTC Brain Tumor Group Study 26951
Martin J. van den Bent,Alba A. Brandes,Martin J.B. Taphoorn,Johan M. Kros,Mathilde C.M. Kouwenhoven,Jean-Yves Delattre,Hans J.J.A. Bernsen,Marc Frenay,Cees C. Tijssen,Wolfgang Grisold,László Sipos,Roelien H. Enting,Pim J. French,Winand N.M. Dinjens,Charles J. Vecht,Anouk Allgeier,Denis Lacombe,Thierry Gorlia,Khê Hoang-Xuan +18 more
TL;DR: The addition of six cycles of PCV after 59.4 Gy of RT increases both OS and PFS in anaplastic oligodendroglial tumors, and 1p/19q-codeleted tumors derive more benefit from adjuvant PCV compared with non-1p/ 19q-deleted tumors.
Journal ArticleDOI
Adjuvant Procarbazine, Lomustine, and Vincristine Improves Progression-Free Survival but Not Overall Survival in Newly Diagnosed Anaplastic Oligodendrogliomas and Oligoastrocytomas: A Randomized European Organisation for Research and Treatment of Cancer Phase III Trial
Martin J. van den Bent,Antoine F. Carpentier,Alba A. Brandes,Marc Sanson,Martin J B Taphoorn,Hans J.J.A. Bernsen,Marc Frenay,Cees C. Tijssen,Wolfgang Grisold,Laslo Sipos,H. Haaxma-Reiche,Johannes M. Kros,Mathilde C.M. Kouwenhoven,Charles J. Vecht,Anouk Allgeier,Denis Lacombe,Thierry Gorlia +16 more
TL;DR: Adjuvant PCV chemotherapy does not prolong OS but does increase PFS in anaplastic oligodendroglioma, and combined loss of 1p/19q identifies a favorable subgroup of oligodENDroglial tumors.
Journal ArticleDOI
Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3
Thierry Gorlia,Martin J. van den Bent,Monika E. Hegi,Monika E. Hegi,René O. Mirimanoff,Michael Weller,J. Gregory Cairncross,Elizabeth Eisenhauer,Karl Belanger,Alba A. Brandes,Anouk Allgeier,Denis Lacombe,Roger Stupp +12 more
TL;DR: An exploratory subanalysis of the EORTC and NCIC data is undertaken to confirm or identify new prognostic factors for survival in adult patients with glioblastoma, derive nomograms that predict an individual patient's prognosis, and suggest stratification factors for future trials.